Jindan Yu, MD, PhD
Professor, Medicine, Hematology Oncology Division; Feinberg School of Medicine
My laboratory studies the genetic and epigenetic mechanisms underlying prostate cancer progression. We take cancer biology, genomics and bioinformatics approaches to examine the transcription factors and regulatory pathways that mediate cancer cell growth and de-differentiation. Based on the genetics and epigenetics of the disease, we also pursue translational studies to define diagnostic/prognostic biomarkers and to develop novel therapeutics for metastatic prostate cancer. Specific projects currently ongoing characterize the downstream pathways and functional roles of TMPRSS2-ERG gene fusion, androgen receptor, and polycomb group protein EZH2 in prostate cancer.